Investigational Drug Information for Obatoclax
✉ Email this page to a colleague
What is the drug development status for Obatoclax?
Obatoclax is an investigational drug.
There have been 19 clinical trials for Obatoclax.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, and Lung Neoplasms. The leading clinical trial sponsors are Gemin X, National Cancer Institute (NCI), and Cephalon.
Summary for Obatoclax
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,287 |
| WIPO Patent Applications | 785 |
| Japanese Patent Applications | 230 |
| Clinical Trial Progress | Phase 2 (2012-08-01) |
| Vendors | 31 |
Recent Clinical Trials for Obatoclax
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer | Cephalon | Phase 3 |
| Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Obatoclax for Systemic Mastocytosis | Gemin X | Phase 2 |
Clinical Trial Summary for Obatoclax
Top disease conditions for Obatoclax
Top clinical trial sponsors for Obatoclax
US Patents for Obatoclax
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
